Biotech · Private company · Lebanon, NH, US
Celdara Medical, LLC
Track this companyFree. Adds Celdara Medical, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- Development of an immunotherapeutic agent for treatment of osteomyelitisFiscal year 2026 · $320.9KNIH RePORTER 1R43AI192073-01A1 · fetched Nov 12, 2026
- Precision CAR-NK therapy for VK4-1 autoreactive B cells in autoimmune diseases: advancing treatment with preserved immune function.Fiscal year 2026 · $320.9KNIH RePORTER 1R43AI197698-01 · fetched Nov 12, 2026
- Development of a Novel, Allogeneic Cell Therapy for Difficult to Treat IBDFiscal year 2026 · $356.3KNIH RePORTER 1R43DK143897-01A1 · fetched Nov 12, 2026
- Engineered Tregs as a therapy to Gaucher syndromeFiscal year 2026 · $310.6KNIH RePORTER 1R43TR006062-01A1 · fetched Nov 12, 2026
- Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF)Fiscal year 2026 · $162KNIH RePORTER 5R25AG078135-05 · fetched Nov 12, 2026
- Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanomaFiscal year 2026 · $1MNIH RePORTER 5R44CA298512-02 · fetched Nov 12, 2026
- Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanomaFiscal year 2025 · $1.2MNIH RePORTER 1R44CA298512-01 · fetched Nov 12, 2026
- Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF)Fiscal year 2025 · $162KNIH RePORTER 5R25AG078135-04 · fetched Nov 12, 2026
- A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndromeFiscal year 2025 · $955.9KNIH RePORTER 5R42AI132047-05 · fetched Nov 12, 2026
- Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic StrokeFiscal year 2025 · $421.1KNIH RePORTER 5R43NS127620-02 · fetched Nov 12, 2026